Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma (MM). The following medical conditions: Pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency virus (HIV) infection, hepatitis B or C infection, stroke or seizure less than or equal to (=140 mg of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication).Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or primary amyloid light-chain amyloidosis.Prior therapy must include an IMiD, PI, and anti-CD38 monoclonal antibody Cohort C: received >= 3 prior lines of therapy that included a PI, an IMiD, an anti-CD38 monoclonal antibody, and an anti-B cell maturation antigen (BCMA) treatment (with CART-T cells or an antibody drug conjugate (ADC) Cohorts A and D: received at least 3 prior MM treatment lines of therapy.Willing and able to adhere to the prohibitions and restrictions specified in this protocol.A female participant of childbearing potential must have a negative pregnancy test at screening.Measurable disease: Cohort A, Cohort C and Cohort D: Multiple myeloma must be measurable by central laboratory assessment.Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.Documented diagnosis of multiple myeloma according to IMWG diagnostic criteria.Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |